Research programme: liposomal nucleic acid therapeutics - Bio-Path Holdings

Drug Profile

Research programme: liposomal nucleic acid therapeutics - Bio-Path Holdings

Alternative Names: BP-100-1.02; BP-100-2.01; BP-1002; Liposomal Bcl-2; Liposomal Bcl2 antisense

Latest Information Update: 20 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Bio-Path Holdings
  • Class Antisense RNA; Small interfering RNA
  • Mechanism of Action Focal adhesion protein-tyrosine kinase inhibitors; Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Follicular lymphoma; Solid tumours

Most Recent Events

  • 19 Jul 2017 Bio-Path Holdings receives notice of allowance for DNAbilize™ technology in USA
  • 05 Apr 2017 Pharmacodynamics data from preclinical studies in Lymphoma presented at the American Association for Cancer Research Annual Meeting (AACR-2017)
  • 01 Apr 2017 Pharmacodynamics data from a preclinical in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top